2. Association of SLC38A3 expression with clinicopathological features in ESCC TMA cohort.
| Clinicopathological features | Total [n (%)] | SLC38A3 level [n (%)] | P | |
| High | Low | |||
| SLC38s, solute carrier family 38; ESCC, esophageal squamous cell carcinoma; TMA, tissue microarray; LNM, lymph node metastasis; AJCC, American Joint Committee on Cancer; OS, overall survival. | ||||
| Gender | 0.589 | |||
| Male | 77 (73.3) | 45 (58.4) | 32 (41.6) | |
| Female | 28 (26.7) | 18 (64.3) | 10 (35.7) | |
| Age (year) | 0.339 | |||
| ≤65 | 54 (51.4) | 30 (55.6) | 24 (44.4) | |
| >65 | 51 (48.6) | 33 (64.7) | 18 (35.3) | |
| LNM | 0.038 | |||
| Yes | 56 (54.4) | 28 (50.0) | 28 (50.0) | |
| No | 47 (45.6) | 33 (70.2) | 14 (29.8) | |
| N stage | 0.462 | |||
| N0+N1 | 79 (77.5) | 48 (60.8) | 31 (39.2) | |
| N2 | 23 (22.5) | 12 (52.2) | 11 (47.8) | |
| Grade | 0.328 | |||
| 1 | 36 (34.3) | 25 (69.4) | 11 (30.6) | |
| 2 | 45 (42.9) | 21 (46.7) | 24 (53.3) | |
| 3 | 24 (22.9) | 10 (41.7) | 14 (58.3) | |
| T stage | 0.235 | |||
| T1+T2 | 16 (15.7) | 12 (75.0) | 4 (25.0) | |
| T3+T4 | 86 (84.3) | 51 (59.3) | 35 (40.7) | |
| AJCC stage | 0.003 | |||
| 1 | 6 (6.0) | 6 (100) | 0 (0) | |
| 2 | 42 (42.0) | 30 (71.4) | 12 (28.6) | |
| 3 | 52 (52.0) | 25 (48.1) | 27 (51.9) | |
| OS | 0.004 | |||
| Dead | 86 (81.9) | 46 (53.5) | 40 (46.5) | |
| Alive | 19 (18.1) | 17 (89.5) | 2 (10.5) | |
| 5-year survival | 0.007 | |||
| Dead | 84 (80.0) | 45 (53.6) | 39 (46.4) | |
| Alive | 21 (20.0) | 18 (85.7) | 3 (14.3) | |